Found Buyers at $64 a few times today. RBLX-- If only I trusted the market here.... Roblox Corporation $65.44 <----------- -1.15(-1.73%) 12:27 PM 05/06/21
Stoney... I have a stock you need to look into. $ALDX $11.70 Huge insider buy this week, big option action last week. And it looks like there was way more. Insider Buying (Last 12 Months): $45,664,999.50 Insider Selling (Last 12 Months): $0.00 It's your wheel-house: Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency. ___________________________________________ EDIT: Look at this! 5/3/2021 Perceptive Advisors Llc Major Shareholder Buy 1,200,000 $12.50 $15,000,000.00 1/19/2021 Perceptive Advisors Llc Major Shareholder Buy 1,368,421 $9.50 $12,999,999.50 1/7/2021 Perceptive Advisors Llc Major Shareholder Buy 500,000 $8.13 $4,065,000.00 7/9/2020 Perceptive Advisors Llc Major Shareholder Buy 3,200,000 $4.25 $13,600,000.00 3/16/2020 Richard Douglas Director Buy 40,000 $2.75 $110,000.00 125,000
Interesting Van, I've tried to capture my wife in the bed a few times with The Bola but it is hard. Here a disturbed women in a hotel is de escalated.
http://archive.fast-edgar.com/20210506/A32VL22DZZ2RJ9Z222JS2ZYR6SPTZZ22N232/ Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights • Recently Announced Phase 3 INVIGORATE Clinical Trial Results Indicated Statistically Significant Activity of Reproxalap in Ocular Itching and Redness Associated with Allergic Conjunctivitis • Top-Line Results from Phase 3 TRANQUILITY and TRANQUILITY-2 Trials of Reproxalap in Dry Eye Disease Expected in the Second Half of 2021 • Initial Phase 2 Clinical Trial Results for ADX-629, a Novel Orally Available Systems-Based RASP Inhibitor with Potential Broad Applicability Across Immune-Mediated Diseases, Expected in the Second Half of 2021 • Raised Gross Proceeds of $125 Million Before Deduction of Underwriting Discounts and Commissions, in Underwritten Public Offering • Projected Cash Runway Through 2023, Including Potential New Drug Applications; Initial Commercialization of Reproxalap, if Approved; and Continued Pipeline Development • Management to Host Conference Call at 8:00 a.m. ET Today LEXINGTON, Mass., May 6, 2021 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2021 and provided recent business highlights. “We expect 2021 to be a catalyst-rich year for Aldeyra as we continue to advance reproxalap, our lead program, toward potential commercialization in anterior ocular inflammatory disease,” stated President and CEO Todd C. Brady, M.D., Ph.D. “We recently completed the Phase 3 INVIGORATE Trial of reproxalap, achieving statistically significant superiority over vehicle across all assessed signs and symptoms of allergic conjunctivitis, including ocular itching and redness. We look forward to meeting with the U.S. Food and Drug Administration in the second half of this year to discuss the INVIGORATE results and the potential submission of a New Drug Application (NDA). In addition, we remain on track to report top-line results in the second half of this year from the Phase 3 TRANQUILITY and TRANQUILITY-2 clinical trials of reproxalap in dry eye disease. 1 “We believe we continue to operate from a position of financial strength,” Dr. Brady stated. “With the recent follow-on public offering, we expect to have sufficient capital to prepare reproxalap for NDA submission and a potential commercial launch, if approved, while investing in the clinical development of ADX-629, ADX-2191, and other product candidates in retinal and systemic immunological diseases with unmet medical need.” Recent Highlights and Program Updates • Primary, Key Secondary, and All Secondary Endpoints Met in Phase 3 INVIGORATE Allergic Conjunctivitis Clinical Trial: In the first-ever Phase 3 clinical trial of a novel investigational product in an allergen chamber, 0.25% reproxalap ophthalmic solution (reproxalap) demonstrated statistically significant improvement over vehicle for the primary endpoint of ocular itching (p<0.0001), the key secondary endpoint of ocular redness (p<0.0001), and the secondary endpoints of ocular tearing and total ocular severity score (each p<0.0001). The results of INVIGORATE, the second positive Phase 3 trial for reproxalap in allergic conjunctivitis, indicate potential clinical utility before and during exposure to moderate to high levels of pollen. • Phase 3 TRANQUILITY and TRANQUILITY-2 Dry Eye Disease Trial Results Expected in Second Half of 2021: Patient enrollment has begun in the dry eye chamber Phase 3 TRANQUILITY Trial of reproxalap. The primary endpoint of the trial is ocular redness, which was statistically lower (p=0.03) for reproxalap relative to vehicle in the TRANQUILITY run-in cohort results announced in January 2021. Tear RASP (reactive aldehyde species) levels will also be assessed. Approximately 150 dry eye disease patients are expected to be enrolled per arm. Reproxalap will be administered four times the day prior to entry into the dry eye chamber, just before entry into the chamber, and 45 minutes after chamber entry. Enrollment in TRANQUILITY is ongoing, and enrollment in the confirmatory TRANQUILITY-2 Trial is expected to begin in the second quarter of 2021. Aldeyra plans to report top-line results from both trials in the second half of this year. • Phase 2 Clinical Trial Results from ADX-629, an Orally Available RASP Inhibitor, Expected Second Half of 2021: Initial Phase 2 clinical results from ADX-629, a novel orally available RASP inhibitor currently undergoing testing in asthma, psoriasis, and COVID-19, are expected in the second half of 2021. ADX-629 represents a first-in-class systems-based therapeutic approach for an orally administered RASP inhibitor, the potential applicability of which could extend to a myriad of immune-mediated diseases that today are treated with single-target drugs that can lead to serious toxicity. 2 • Public Offering Completed: Aldeyra sold 10,000,000 shares of its common stock at a public offering price of $12.50 per share in an underwritten public offering. The offering generated gross proceeds of $125.0 million and net proceeds of $117.3 million after deducting underwriting discounts, commissions, and estimated offering expenses.
Van I'm looking through their portfolio it's deep with some possibility of SARS/Covid press releases- Insider bUying a while ago as well) )
Here is my theory Van. There was a secondary at $12 something. Stock is below secondary price certain shareholders are ticked off and to support the idea the insider buying<------ Aldeyra price target raised to $25 from $22 at Citi 04/28 ALDX Citi analyst Yigal Nochomovitz raised the firm's price target on Aldeyra Therapeutics to $25 from $22 and keeps a Buy rating on the shares. The analyst is comfortable raising the probability of success to 95% for allergic conjunctivitis and to 85% for dry eye after the company delivered on a "bull case" for reproxalap in allergic conjunctivitis. Everything really does sound pretty good otherwise eye care is important. I wonder about motivation of the Insider Buy.... Whereas with IronWood IRWD it may be more specific to something good...~stoney
Check this out- Aldeyra 10M share Secondary priced at $12.50 04/28 ALDX The deal priced below the last closing price of $13.93. Jefferies and SVB Leerink are acting as joint book running managers for the offering. So shareholders were at $14 when they got the news shares sold at $12.50 Totally pissed off shareholder base!